The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 23, 2022

Filed:

Feb. 04, 2019
Applicants:

Georgia Tech Research Corporation, Atlanta, GA (US);

University of Virginia Patent Foundation, Charlottesville, VA (US);

North Carolina State University, Raleigh, NC (US);

Inventors:

Thomas H. Barker, Atlanta, GA (US);

Ashley Carson Brown, Atlanta, GA (US);

Louis Andrew Lyon, Irvine, CA (US);

Sarah E. Stabenfeldt, Tempe, AZ (US);

Nicole Welsch, Berlin, DE;

John Nicosia, Atlanta, GA (US);

Assignees:
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 47/69 (2017.01); A61K 47/58 (2017.01); A61P 35/00 (2006.01); C08L 33/24 (2006.01); C08L 33/02 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
A61K 47/6913 (2017.08); A61K 47/58 (2017.08); A61K 47/6903 (2017.08); A61P 35/00 (2018.01); A61K 45/06 (2013.01); C08L 33/02 (2013.01); C08L 33/24 (2013.01); C08L 2203/02 (2013.01);
Abstract

Ultra-low crosslinked microgels made of an ultra-low crosslinked polymer are provided. The microgels, also referred to as Platelet-like Particles (PLPs), preferably have <0.5% crosslinking densities. One or more of the polymers are conjugated with a fibrin-binding element or moiety, preferably H6, in an amount effective to confer to the microgel selective binding to fibrin under physiological conditions. The PLPs can recapitulate multiple key functions of platelets including binding, stabilizing and enhancing fibrin clot formation, responsiveness to injury cues, and induction of clot contraction. In a preferred embodiment, the microgel or PLP has little or no binding to soluble fibrinogen under physiological conditions compared to its binding to fibrin. The microgels or PLPs are prepared using crosslinker-free synthesis conditions, and can promote or induce clotting and clot contraction.


Find Patent Forward Citations

Loading…